Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph‐node invasion
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Matias A Bustos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI) at Providence Saint John's Health Center (SJHC), Santa Monica, C…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, MicroRNAs, RNA, Messenger, Lymphatic Metastasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mr. Jerome M. Applebaum and the Charles B. Fiscus Foundation, Ensign Cancer Research Foundation, Henry L. Guenther Foundation.
Abstract (Originalsprache)
Background
Nomograms or comparable techniques can be used to determine which patients with prostate cancer (PCa) will benefit from extended pelvic lymph node dissection (ePLND). While nomograms help guide clinical decisions, ∼80% of the patients undergo unnecessary ePLND. This pilot study aims to identify both transcriptomic mRNA and microRNA (miR) signatures in primary PCa tumours that are associated with the presence of lymph node metastasis (LNM).
Methods
Primary PCa tumours obtained from 88 patients (pathologically diagnosed as N0 [pN0, n = 44] or as N1 [pN1, n = 44]) were profiled using two different probe‐based captured direct assays based on next‐generation sequencing and targeting 19398 mRNA transcripts (human transcriptome panel [HTP] dataset) and 2083 miRs (miRs whole‐transcriptome assay [WTA] dataset). The TCGA‐PRAD (pN0 [ n = 382] and pN1 [ n = 70]) and GSE220095 (pN0 [ n = 138] and pN1 [ n = 17]) datasets were used for validation using bioinformatic analyses.
Results
A four‐mRNA signature ( CHRNA2 , NPR3 , VGLL3 and PAH ) was found in primary tumour tissue samples from pN1 PCa patients, and then it was validated using the TCGA‐PRAD and GSE220095 datasets. Adding serum prostate‐specific antigen (PSA) values to the four‐gene signature increased the performance to identify pN1 (HTP [AUC = .8487, p = 2.18e‐09], TCGA‐PRAD [AUC = .7150, p = 8.66e‐08] and GSE220095 datasets [AUC = .8772, p = 4.09e‐07]). Paired miR analyses showed that eight miRs were significantly upregulated in primary PCa that were pN1 ( p < .01). The eight‐miR signature performance increased when adding PSA (WTA dataset [AUC = .8626, p = 4.66e‐10]) or Grade group (WTA dataset [AUC = .8689, p = 2e‐10]). When combining the miR/mRNA signatures (miR‐663b, CHRNA2 and PAH ) with PSA levels, it showed the best performance to distinguish pN1 from pN0 PCa patients.
Conclusion
This study found miR/mRNA signatures in primary PCa tumours that in combination with serum PSA levels may complement nomograms for better detection of PCa patients with LNM and triage patients into better surgical decision‐making. Key points Primary prostate cancer (PCa) tumours from patients pathologically diagnosed as N0 (pN0) or N1 (pN1) were dually assessed for microRNA (miRs) and mRNA levels using an NGS‐based assay. A four‐mRNA and an eight‐miRNA signature were found. The mRNA signatures were further validated using two datasets. The combination of serum prostate‐specific antigen (PSA) levels or Grade Group with the miR/mRNA signatures separates pN1 from pN0 PCa patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI) at Providence Saint John's Health Center (SJHC), Santa Monica, California, USA.
- Department of Urology and Urologic Oncology, SJCI at Providence SJHC, Santa Monica, California, USA.
- Department of Genome Sequencing Center, SJCI at Providence SJHC, Santa Monica, California, USA.
- Division of Surgical Pathology, Providence SJHC, Santa Monica, California, USA.
ORCID-Profile: Matias A Bustos, Dave S B Hoon
Förderung
- Mr. Jerome M. Applebaum and the Charles B. Fiscus Foundation
- Ensign Cancer Research Foundation
- Henry L. Guenther Foundation
Zitieren
APA
Bustos, M. A., Chong, K. K., Koh, Y., Kim, S., Ziarnik, E., Ramos, R. I., Jimenez, G., Krasne, D. L., Allen, W. M., Wilson, T. G., & Hoon, D. S. B. (2025). Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph‐node invasion. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70288
Vancouver
Bustos MA, Chong KK, Koh Y, Kim S, Ziarnik E, Ramos RI, et al. Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph‐node invasion. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70288
BibTeX
@article{Bustos2025,
author = {Bustos, Matias A and Chong, Kelly K and Koh, Yoko and Kim, SooMin and Ziarnik, Eleanor and Ramos, Romela I and Jimenez, Gianna and Krasne, David L and Allen, Warren M and Wilson, Timothy G and Hoon, Dave S B},
title = {Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph‐node invasion},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70288}
}
EUVIMED